(HB)); 465 of them (19.4%) were on prophylaxis. These rates were higher in patients with severe haemophilia (45.4%) and severe paediatric cases (72.5%). Based on the information recorded in this study we analysed the current situation of prophylaxis therapy administered to patients with HA in Spain, as well as their orthopaedic status.
Prophylaxis was used in 399 (19.2%) patients with HA; such prophylaxis was primary (PP) in 20. 3% On the basis of the information from the Spanish Epidemiological Study [1] we aimed to achieve a deeper knowledge of various issues involved in clinical practice like the real current situation of primary and secondary prophylactic treatment provided to both paediatric and adult haemophilia A (HA) patients in our country, as well as their current orthopaedic status according to the Pettersson score [3] and the implementation of central venous access devices (CVAD) insertion often required for an adequate compliance of therapeutic schedules involving frequent intravenous infusions [4] .
MATERIALS AND METHODS
Data used for our evaluation were obtained from the database made up for the Spanish Haemophilia Epidemiological Study, involving 2081 HA patients registered and managed in 51 haemophilia treatment centres [1] .
The degree of severity of haemophilia was sorted according to previously published standard criteria related to FVIII plasma levels as severe (<0.01 U dL -1 ), moderate (≥0.01 U dL -1 to < 0.05 U dL -1 ) and mild (≥0.05 U dL -1 to 0.4 U dL -1 ) [5] . Patients ≥14 years of age were rated as adults and those <14 as paediatric.
Definition of the type of prophylactic treatment was made following the recommendations of the PEDNET group (European Paediatric Network for Haemophilia Treatment) [6] as:
-A primary prophylaxis (APP): Regular continuous (minimum 46 weeks a year) treatment started after the first joint bleed recorded and before the age of 2 years. treatment started before the age of 2 years without any evidence of a previous joint bleed.
-A secondary prophylaxis (ASP): Regular continuous (long term) treatment started after 2 or more joint bleeds recorded or at an age >2.
-B secondary prophylaxis (BSP): Intermittent regular (short term) treatment provided in order to cover frequent haemarthroses.
Assessment of joint status was made by visualisation of X-rays of elbows, knees and ankles according to the Pettersson score [3] ; scores of ≥3 for any particular joint were consistent with established haemophilic arthropathy (EHA).
Information related to CVAD was focused on particular aspects like catheter duration and incidence of the two most frequent complications associated to their use: infection and thrombosis.
Statistical analysis
A descriptive analysis was done, using absolute and relative frequencies for qualitative variables and centralization and dispersion measures for quantitative variables. 
Prophylaxis in haemophilia A patient population
Evaluation of this group of 2081 HA patients showed that 399 (19.2%) of them were on prophylaxis: primary in 81 cases (20.3 %), secondary in 303 (75.9%) and undetermined in 15 (3.7%). Details are shown in Table 1 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In the analysis by groups of age and type of treatment we founded the following results (see Table 2 ):
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-Only a minor proportion of adult HA patients (215; 13.4%) were on prophylactic therapy: primary in 13 (6.1%) and secondary in 196 (92.2%).
-The rate of paediatric patients on prophylaxis was far higher, as expected (184; 38.8%); rates of primary (PP) and secondary prophylaxis (SP) for this age group were 26.9% (68 cases) and 58.1% (107 cases) respectively. Among the 313 severe HA patients receiving prophylaxis, EHA was detected in 142 of them (45.4%), but only in 2.9% of patients under PP versus 59% of patients receiving SP (p<0.001) ( Table 4 ).
Prophylaxis in severe haemophilia A patient population
For all 433 treated severe HA adult patients recorded, EHA was found in 74.4% (322/433) of them and rates of chronic joint damage were significantly higher for patients receiving on demand treatment (79.4%) than for patients receiving prophylaxis with regular factor VIII infusions (66.1%), p=0.002. There was no EHA in adult severe HA patient on PP, whereas 70.4% on SP had joint damage (p<0.00001) ( Table 4 ).
This evaluation was also made in 148 paediatric severe HA patients on prophylaxis.
Pettersson scores consistent with EHA were found in 33 (22.3%) of them, but only in 3.3% (2/60) of paediatric severe HA patients on APP or BPP; however signs of chronic joint damage were found in 37.8% (31/82) of children on ASP or BSP (p<0.00001). 
Frequency of infusions and bleeds
During the study period mean number of factor VIII concentrate infusions for the 399 Mean number of annual bleeding episodes for HA patients on prophylaxis was 2.9
(range 0-78, SD: 6.53).
Infusion routes of factor VIII concentrates
Factor concentrate was mostly administered through peripheral veins to HA individuals on regular prophylaxis (87.2%). Only in 9.5% of patients a CVAD was required and in 1.7% of cases both types of venous access were used. Important differences were found in CVAD insertion frequencies between patients on PP (23.4%) and SP (7.3%).
Complications associated to the use of CVAD were reported in 29 of 41 (70.7%) of catheters inserted. Infection was the most common of these complications (11 patients; 37.9%) with a rate of 0.73 patient days throughout 2006. No cases of thrombosis were reported. CVAD malfunctioning was recorded in 4 patients (13.8%) and some type of minor undetermined complication in almost half of cases (14; 48.3%). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Our results show that 19.2% of HA patients are following some type of prophylaxis treatment, consistently with data published by Biss et al (20.3%) [7] , but not with those reported by Plug et al (29%) [9] . Rates of prophylaxis available in Japanese series are very surprisingly heterogeneous, considering that they offer information on patients treated in the same country; thus Ono et al [12] report rates of prophylaxis of 67.2%, whereas for Taki et al [13] it is of only 11.6%.
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When we focused our analysis on severe HA patients (682 altogether) we found out that almost half of them (313; 45.9%) were on some type of prophylactic treatment, a rate similar to that reported by Butler et al (44%) [10] but lower than in the Dutch (Plug et al; 67.6%) [9] or Canadian series (Biss et al; 62.3%). Comparison of our data with those in this latter study is difficult to carry out because prophylaxis as considered in this paper refers to factor VIII treatment administered at least once a week during 45 weeks a year, whereas our patients received factor VIII infusions three times a week. were on some sort of prophylaxis treatment consistent with 72.5% from our epidemiological study (using 14 as a top age for patients being considered as paediatric)
after exclusion of undetermined cases. Differences in age cut-offs between both groups must be taken into account when comparing results from both studies. Other authors like Plug et al set this cut-off at the age of 16 and report prophylaxis rates of 86% for severe HA patients [9] . Great heterogeneity existing in classification of age groups can be an issue when interpreting the results from different studies. [15] ; they found that after 6 years of observation, patients under prophylaxis obtained better orthopaedic and radiological scores than patients following on demand therapy even though secondary prophylaxis couldn't impede the progression of the EHA.
Moreover, in our study we found that primary prophylaxis resulted strongly protective for the adult population.
Although no differences in the degree of joint damage were noticed in the population of severe paediatric patients treated on demand versus those treated with prophylaxis. This results maybe due to the delay on the onset of the secondary prophylaxis in our country.
When we did this analysis in function of the type of prophylactic treatment administered, we found that PP resulted protective for the development of EHA in the paediatric population. Early onset of prophylactic treatment is definitely crucial for the [9] , long before it became popular in other countries like Spain (where SP began to be used in the late seventies and the PP in the early nineties, approximately) and this may have translated into a steady rate of arthropathy of about 30%, reflected in the Spanish epidemiological study [1] . In our experience the most commonly affected joints were ankles followed by knees and elbows.
Patients for whom a CVAD insertion was decided were more commonly those on PP, which is not surprising considering that patients in this group are more often children under the age of 2 for whom recurrent intravenous infusions via peripheral veins is impractical and may seriously jeopardise compliance with regular prophylaxis.
Data collected from our study disclose that about one in four of our patients on PP (23.5%) had a CVAD inserted for this purpose, which is similar to rates previously reported by Valentino et al [16] ; other research groups however are far more active in the usage of such devices in patients on PP who have one inserted in up to 82% of cases according to Blanchette et al [10, 14] .
Major complications of CVAD are infrequent [16] . As already mentioned above catheter associated infections are the most frequent amongst these patients for whom frequencies of 0.28 to 1.6 patient days for individuals without inhibitors have been published up to 2003 [17] . Thus our infection rate (0.73 per 1000 patient days) lies within the range just mentioned. No cases of catheter-triggered thrombosis have been collected from our study, consistently with data from the paper by Ljung et al [18] enrolling a similar number of patients with a CVAD. Malfunctioning frequencies in this study were 18.8% during an average follow-up period of 13 months, not far from our 13.8% in a one-year follow-up time.
CONCLUSIONS
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